Similarly, the GLP-1 agonist, Semaglutide has recently been shown to improve outcomes in patients with HF of both preserved and reduced ejection fraction and obesity (irrespective of diabetes status) in the large randomized controlled SELECT trial [72]. Here, GCG is linked to hydrops fetalis.